Fate Therapeutics/$FATE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fate Therapeutics
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Ticker
$FATE
Sector
Primary listing
Employees
161
Headquarters
Website
FATE Metrics
BasicAdvanced
$228m
-
-$1.09
2.14
-
Price and volume
Market cap
$228m
Beta
2.14
52-week high
$2.88
52-week low
$0.91
Average daily volume
4m
Financial strength
Current ratio
5.85
Quick ratio
5.746
Long term debt to equity
40.09
Total debt to equity
42.728
Profitability
EBITDA (TTM)
-125.838
Gross margin (TTM)
-1,284.83%
Net profit margin (TTM)
-2,056.79%
Operating margin (TTM)
-2,190.06%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-25.29%
Return on equity (TTM)
-55.50%
Valuation
Price to revenue (TTM)
36.992
Price to book
1.27
Price to tangible book (TTM)
1.27
Price to free cash flow (TTM)
-2.161
Free cash flow yield (TTM)
-46.27%
Free cash flow per share (TTM)
-0.907
Growth
Revenue change (TTM)
-52.64%
Earnings per share change (TTM)
-26.88%
3-year revenue growth (CAGR)
-64.13%
10-year revenue growth (CAGR)
5.34%
3-year earnings per share growth (CAGR)
-23.30%
10-year earnings per share growth (CAGR)
-0.16%
What the Analysts think about FATE
Analyst ratings (Buy, Hold, Sell) for Fate Therapeutics stock.
FATE Financial Performance
Revenues and expenses
FATE Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs